@article{64b3fe2ecb2648719efb93dca88c6c25,
title = "Dr. Aman et al. reply",
author = "Aman, {Michael G.} and Arnold, {L. Eugene} and Luc Lecavalier and Hollway, {Jill A.} and Mulick, {James A.} and McDougle, {Christopher J.} and Swiezy, {Naomi B.} and Stigler, {Kimberly A.} and Handen, {Benjamin L.} and Cynthia Johnson and Benedetto Vitiello and Karen Bearss and James Dziura and Lawrence Scahill",
note = "Funding Information: This work was funded by the National Institute of Mental Health by the following RUPP grants: Ohio State University, U10MH66768 ; Indiana University, U10MH66766 ; and Yale University, U10MH66764 . Johnson & Johnson Pharmaceutical Research & Development provided active risperidone for the study. Funding Information: Disclosure: Dr. Aman received recent contract support from Johnson & Johnson and Bristol-Myers Squibb. Dr. Arnold has served as a consultant to Abbott, Neuropharm, Novartis, Arganon, Shire, Targacept, and Noven; and received research support from CureMark, Neurophram, Shire, and Eli Lilly; and has served as a speaker for Shire and Novartis. Dr. Scahill has receieved recent contract support from Boehringer–Ingelheim, Bristol-Myers Squibb, Shire, Neuropharm, Supernus, and Janssen. Dr. McDougle has served as a consultant to, has received research support from, and has served on the speakers' bureau of Bristol-Myers Squibb Co. Drs. Stigler, Vitiello, Swiezy, Johnson, Dziura, Lecavalier, Handen, Mulick, Bearss, and Hollway report no biomedical financial interests or potential conflicts of interest. ",
year = "2010",
month = apr,
doi = "10.1097/00004583-201004000-00016",
language = "English (US)",
volume = "49",
pages = "407--408",
journal = "Journal of the American Academy of Child and Adolescent Psychiatry",
issn = "0890-8567",
publisher = "Elsevier Limited",
number = "4",
}